Home › Funds › Parkman Healthcare Partners LLC › ADPT
Parkman Healthcare Partners LLC position in ADPT
ADAPTIVE BIOTECHNOLOGIES COR · Health Care
Parkman Healthcare Partners LLC reported holding 600,053 shares of ADPT (ADAPTIVE BIOTECHNOLOGIES COR) in its Q3 2026 13F filing — a position valued at US$17.3M, representing 1.57% of its reported portfolio and ranking #21 among its reported holdings. Parkman Healthcare Partners LLC has disclosed ADPT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's ADPT position evolved
Parkman Healthcare Partners LLC first disclosed a stake in ADPT in Q4 2025 at 401,730 shares (US$6.5M). The position peaked in Q3 2026 at 600,053 shares, worth US$17.3M. Across 4 filings, Parkman Healthcare Partners LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 600,053 shares valued at US$17.3M — an increase of 113,069 shares quarter over quarter.. Notable position changes include a 37% increase in Q1 2026 (shares rose 55% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 401.73K | $6.52M | New |
| Q1 2026 | 551.82K | $7.66M | Add |
| Q2 2026 | 486.98K | $10.45M | Reduce |
| Q3 2026 | 600.05K | $17.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ADPT and 13F data
ADPT (ADAPTIVE BIOTECHNOLOGIES COR) is a Health Care company. 58 other funds we track also report a position in ADPT — the largest reported positions include Viking Global Investors (US$643.4M), VIKING GLOBAL INVESTORS LP (US$643.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$136.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ADPT
- Viking Global Investors 29.99M sh · $643.37M · Q2 2026
- VIKING GLOBAL INVESTORS LP 29.99M sh · $643.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.71M sh · $136.00M · Q3 2026
- Aristotle Atlantic Partners, LLC 1.85M sh · $53.59M · Q3 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.26M sh · $36.32M · Q3 2026
- Blue Water Life Science Advisors, LP 1.01M sh · $29.19M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $26.11M · Q2 2026
- Granite Investment Partners, LLC 628.10K sh · $18.15M · Q3 2026
- NEXT CENTURY GROWTH INVESTORS LLC 622.89K sh · $18.00M · Q3 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held ADPT?
Parkman Healthcare Partners LLC has disclosed ADPT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Parkman Healthcare Partners LLC's current position in ADPT?
As of Q3 2026, Parkman Healthcare Partners LLC holds 600.05K shares of ADPT (ADAPTIVE BIOTECHNOLOGIES COR), valued at $17.34M, representing 1.57% of its reported portfolio and ranking #21.
Has Parkman Healthcare Partners LLC been buying or selling ADPT?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in ADPT. The position peaked in Q3 2026 at 600.05K shares.
Which other funds hold ADPT?
Other major institutional holders of ADPT include Viking Global Investors, VIKING GLOBAL INVESTORS LP, DRIEHAUS CAPITAL MANAGEMENT LLC, among 58 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.